neratinib 40 mg Tablet, 180-count — NDC 46014-2400-8 (Billing 46014-2400-08)
This is a package of 180 tablets of neratinib 40 mg Tablet from Excella GmbH & Co. KG, first listed with the FDA Jul 2017 and currently FDA-listed.
NDC database record
One package, one record: these facts belong to NDC 46014-2400-8 alone.
- Record
- FDA NDC Directory package listing · Human prescription drug
- Code segments
- 46014 labeler · 2400 product · 8 package
- Package marketed since
- Jul 17, 2017
- Listing certified through
- Dec 31, 2026
- Barcode (UPC-A, from the NDC)
- 3 4601424008 8
- FDA record last changed
- Jul 24, 2026
Identity & classification
Regulatory identifiers FDA, NLM and CMS codes for this package
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- FDA label on DailyMed · label index refreshed Nov 20, 2026
- RxNorm (NLM RxNav) · catalog refreshed Nov 19, 2026
- Medi-Span GPI (licensed)
- First Databank (licensed) · refreshed Nov 19, 2026
Clinical
- Neratinib (Nerlynx) treats HER2-positive breast cancer in adults. On its own, it's used after trastuzumab-based therapy for early-stage disease. With capecitabine, it's used for ad...
- Don't double up. Skip the missed dose and take your next one at the usual time. Try to take it with food at about the same time each day.
- What happens if I miss a dose of Neratinib?
- Diarrhea is very common, so planning ahead matters. Your team will likely have you start loperamide with your first dose, or build up the dose over two weeks. Call them if diarrhea...
Patient education
Drug interactions
Supplement & herbal interactions
Some supplements/herbs that may interact with Neratinib Maleate — tap one for details:
Where does this data come from?
- MedlinePlus (NLM) · refreshed Nov 19, 2026
- FDA label on DailyMed · label index refreshed Nov 20, 2026
Ask a licensed pharmacist directly — free, answered by our team.
Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per each | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | Not in the retail survey — common for institutional, discontinued, or low-volume packs. | |
| Medicaid paysCMS SDUD · 12 mo | No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data. | |
| Medicare drug plans payPart D · quarterly | No Part D plan price is available for this NDC in our data. | |
Where does this data come from?
- CMS NADAC weekly file
- CMS ASP pricing files · refreshed Nov 20, 2026
- CMS Medicaid State Drug Utilization Data · refreshed Nov 19, 2026
- CMS Part D plan pricing files · refreshed Oct 24, 2026
- VA National Acquisition Center price file
Packaging — all sizes for this product
| Package NDC | Description | Marketing start | Marketing end | Status |
|---|---|---|---|---|
| 46014-2400-03 46014-2400-3 Main listing | 133 TABLET in 1 BOTTLE | — | — | Active |
| 46014-2400-08 You're viewing this | 180 TABLET in 1 BOTTLE | — | — | Active |
You're viewing the largest of 2 pack sizes for this product.
Pack size FAQ
What quantity is in this package?
How does this package differ from NDC 46014-2400-03?
What NDC number is used to bill for this package of neratinib 40 mg Tablet?
Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| neratinib 40 mgthis 46014-2400-08 | Excella | 180 tablets | — | — | FDA listed | — |
| Nerlynx 40 mg 70437-0240-18 | Puma | 180 tablets | — | — | FDA listed | — |
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- FDA Orange Book · refreshed Nov 6, 2026
- CMS NADAC weekly file
Availability & generic status
We did not find an FDA-approved generic match for this exact strength, form and route.
Where does this data come from?
- FDA Orange Book · refreshed Nov 6, 2026
Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
🧪 Avoiding an ingredient? See Neratinib inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.
Where does this data come from?
IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.- FDA label on DailyMed · label index refreshed Nov 20, 2026
- FDA openFDA NDC Directory · synced Nov 19, 2026
Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
Manufacturer & labeler
More NDCs from Excella GmbH & Co. KG labeler code 46014
- Temozolomide 1 kg/kg Powder NDC 46014-1450-2
- Temozolomide 1 kg/kg Powder NDC 46014-1460-1
- Ropivacaine Hydrochloride 1 kg/kg Injection, Solution NDC 46014-1470-1
- Buspirone Hydrochloride sieved 1 kg/kg Powder NDC 46014-1480-1
- Timolol maleate 1 kg/kg Powder NDC 46014-1490-1
- Methotrexate Disodium 1 kg/kg Powder NDC 46014-1500-1
- capecitabine 500 mg Tablet, Film Coated NDC 46014-4751-2
- macitentan 10 mg Tablet, Film Coated NDC 46014-5010-1
- Emtricitabine 200 mg Capsule NDC 46014-6010-1
- Uptravi .4 mg Capsule NDC 46014-6040-6
- Uptravi .6 mg Capsule NDC 46014-6060-6
- Uptravi 1 mg Capsule NDC 46014-6100-6
Where does this data come from?
- FDA openFDA NDC Directory · synced Nov 19, 2026
- Drugs@FDA
Full prescribing information FDA SPL
📄 FDA label ▾
No FDA label is on file for this product yet. Labels load from openFDA / DailyMed and refresh weekly.
Reported adverse events (FAERS)
Top reported reactions
Age at onset
Reporter sex
Serious outcomes
Where does this data come from?
About this NDC listing & data coverage
What "drug for further processing" means
FDA lists this package under the "drug for further processing" marketing category: Excella GmbH & Co. KG supplies it to other companies for further processing or repackaging (blister cards that are later repackaged or co-packaged are a common example). The units themselves are a finished dosage form — which is why pricing or Medicaid data can still appear — but this exact package code may not be the presentation a retail pharmacy dispenses.
What data is (and isn’t) available for this NDC — tap to expand
| NDC identity (package / product / labeler codes) | ✓ Available |
| Labeler | ✓ Available |
| Product & package description | ✓ Available |
| Marketing category & status | ✓ Available |
| Active ingredient / dosage form / route | ✓ Available |
| FDA label (SPL via DailyMed) | ✓ Available |
| Package photos | — Not published for this NDC No photo available yet for this listing. |
| Inactive ingredients (structured) | — Not published for this NDC The labeler did not submit a structured excipient list, or no SPL is available. |
| NADAC pharmacy acquisition price (CMS) | — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey. |
| Orange Book / therapeutic-equivalence data | — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope. |
| HCPCS J-code billing crosswalk | — Not published for this NDC Most self-administered / retail products have no J-code — that is normal. |
| Medicaid utilization (CMS SDUD) | — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold. |